Tufton Capital Management Has $2.46 Million Stock Position in Danaher Co. (NYSE:DHR)

Tufton Capital Management boosted its stake in shares of Danaher Co. (NYSE:DHR) by 24.1% during the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 10,614 shares of the conglomerate’s stock after buying an additional 2,062 shares during the period. Tufton Capital Management’s holdings in Danaher were worth $2,455,000 as of its most recent filing with the SEC.

Several other hedge funds have also recently bought and sold shares of DHR. Banco Santander S.A. bought a new position in shares of Danaher during the 3rd quarter worth approximately $683,000. First Citizens Bank & Trust Co. grew its stake in shares of Danaher by 0.6% during the 4th quarter. First Citizens Bank & Trust Co. now owns 26,611 shares of the conglomerate’s stock worth $6,156,000 after acquiring an additional 149 shares in the last quarter. Allspring Global Investments Holdings LLC grew its stake in shares of Danaher by 48.1% during the 4th quarter. Allspring Global Investments Holdings LLC now owns 296,996 shares of the conglomerate’s stock worth $68,707,000 after acquiring an additional 96,395 shares in the last quarter. Parkside Financial Bank & Trust grew its stake in shares of Danaher by 4.8% during the 3rd quarter. Parkside Financial Bank & Trust now owns 3,080 shares of the conglomerate’s stock worth $764,000 after acquiring an additional 142 shares in the last quarter. Finally, Keybank National Association OH grew its stake in shares of Danaher by 0.5% during the 3rd quarter. Keybank National Association OH now owns 553,155 shares of the conglomerate’s stock worth $137,238,000 after acquiring an additional 2,567 shares in the last quarter. 79.05% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Danaher

In other news, SVP Daniel Raskas sold 23,757 shares of the business’s stock in a transaction dated Monday, February 26th. The stock was sold at an average price of $252.00, for a total transaction of $5,986,764.00. Following the sale, the senior vice president now directly owns 38,102 shares in the company, valued at $9,601,704. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. In related news, Director Walter G. Lohr sold 3,289 shares of the company’s stock in a transaction that occurred on Thursday, February 15th. The stock was sold at an average price of $251.15, for a total value of $826,032.35. Following the sale, the director now directly owns 14,129 shares in the company, valued at $3,548,498.35. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, SVP Daniel Raskas sold 23,757 shares of the company’s stock in a transaction that occurred on Monday, February 26th. The shares were sold at an average price of $252.00, for a total value of $5,986,764.00. Following the completion of the sale, the senior vice president now owns 38,102 shares in the company, valued at $9,601,704. The disclosure for this sale can be found here. Insiders have sold a total of 32,957 shares of company stock worth $8,265,802 over the last 90 days. Insiders own 11.10% of the company’s stock.

Danaher Stock Performance

DHR stock traded down $2.29 during midday trading on Thursday, reaching $237.10. 1,711,446 shares of the company were exchanged, compared to its average volume of 2,692,046. Danaher Co. has a one year low of $182.09 and a one year high of $259.00. The company has a debt-to-equity ratio of 0.31, a current ratio of 1.68 and a quick ratio of 1.37. The firm has a market capitalization of $175.58 billion, a price-to-earnings ratio of 37.46, a price-to-earnings-growth ratio of 3.65 and a beta of 0.83. The business has a 50-day moving average price of $249.28 and a two-hundred day moving average price of $229.86.

Danaher (NYSE:DHR) last posted its quarterly earnings results on Tuesday, January 30th. The conglomerate reported $2.09 EPS for the quarter, beating analysts’ consensus estimates of $1.91 by $0.18. The business had revenue of $6.41 billion during the quarter, compared to the consensus estimate of $6.10 billion. Danaher had a return on equity of 12.25% and a net margin of 17.26%. Danaher’s revenue for the quarter was down 10.2% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $2.87 earnings per share. Equities research analysts forecast that Danaher Co. will post 7.62 EPS for the current year.

Danaher Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, April 26th. Shareholders of record on Thursday, March 28th will be given a $0.27 dividend. This represents a $1.08 dividend on an annualized basis and a yield of 0.46%. The ex-dividend date of this dividend is Wednesday, March 27th. This is a boost from Danaher’s previous quarterly dividend of $0.24. Danaher’s payout ratio is currently 16.90%.

Analyst Upgrades and Downgrades

DHR has been the subject of several research reports. KeyCorp raised their price target on shares of Danaher from $260.00 to $290.00 and gave the stock an “overweight” rating in a research note on Thursday, February 1st. JPMorgan Chase & Co. raised their target price on shares of Danaher from $250.00 to $270.00 and gave the company an “overweight” rating in a research note on Wednesday, December 20th. Barclays raised their target price on shares of Danaher from $240.00 to $260.00 and gave the company an “equal weight” rating in a research note on Wednesday, April 10th. Raymond James raised their target price on shares of Danaher from $240.00 to $270.00 and gave the company an “outperform” rating in a research note on Wednesday, January 31st. Finally, HSBC raised shares of Danaher from a “hold” rating to a “buy” rating and raised their target price for the company from $250.00 to $280.00 in a research note on Wednesday. Six investment analysts have rated the stock with a hold rating and ten have issued a buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $268.27.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.